Records containing: Ovarian Cancer
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2024-09-19Phase I Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer
-
CLINICAL_TRIALS study record update · 2024-09-04Asian Multicenter Prospective Study of Circulating Tumor DNA Sequencing: A-TRAIN
-
CLINICAL_TRIALS study record update · 2024-08-29A Phase 2 Study of HS-20089 for Injection in Patients With Recurrent or Metastatic Ovarian Cancer and Endometrial Cancer
-
CLINICAL_TRIALS study record update · 2024-08-28Neoadjuvant RC48 Plus Carboplatin for HER2-expressing Advanced Ovarian Cancer: a Prospective Phase 2 Exploratory Study
-
CLINICAL_TRIALS study record update · 2024-08-27A Multicenter, Open-label, Single-arm, Phase 2 Study to Evaluate the Efficacy and Safety of JPI-547, a PARP/TNKS Dual Inhibitor in Platinum-resistant, Advanced/Relapsed Ovarian Cancer Subjects Previously Treated With a PARP Inhibitor
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2024-08-23Pilot Study of Liposomal Bupivacaine Redosing in Patients Undergoing Major Gynecologic Procedures: A Quality Improvement Project in Post-operative Pain
-
CLINICAL_TRIALS study record update · 2024-08-23An Exploratory Study to Determine the Optimal Timing of BR55 Contrast Enhanced Ultrasound (CEUS) of the Ovaries in Pre-menopausal Women
-
CLINICAL_TRIALS study record update · 2024-08-20A Phase 1b/2 Open Label, Dose Escalation Study of AMG 655 in Combination With AMG 479 in Subjects With Advanced, Refractory Solid Tumors
-
CLINICAL_TRIALS study record update · 2024-08-20Phase IIA Trial of Delayed Initiation of Olaparib Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer
-
CLINICAL_TRIALS study record update · 2024-08-16Exosome-based OCS Scores for Predicting Ovarian Cancer Recurrence: a Prospective Multicenter Observational Cohort
-
CLINICAL_TRIALS study record update · 2024-08-14Fluzoparib Combined With Dalpiciclib for Platinum Resistant Recurrent Ovarian Cancer: a Phase II Clinical Study
-
CLINICAL_TRIALS study record update · 2024-08-13Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Antitumor Activity of TNG348 Single Agent and in Combination With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or Other HRD+ Solid Tumors
-
CLINICAL_TRIALS study record update · 2024-08-13A Single-Arm, Open-Label Clinical Study to Evaluate the Safety, Tolerance and Preliminary Efficacy of KM1 Oncolytic Vaccinia Virus Injection Combined With Chemotherapy in Subjects With Recurrent or Refractory Ovarian Cancer
-
CLINICAL_TRIALS study record update · 2024-08-12ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK
-
CLINICAL_TRIALS study record update · 2024-08-09Metabolic Tracing of Tumour and T Cells in the Ascites of Ovarian Cancer Patients
-
CLINICAL_TRIALS study record update · 2024-08-09Assessments of Genetic Counseling Augmented With an Educational Video or Pamphlet Versus Traditional Counseling
-
CLINICAL_TRIALS study record update · 2024-08-09Secondary Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Recurrent Ovarian Cancer Patients With PARP Inhibitors Resistance: a Phase II Clinical Study
-
CLINICAL_TRIALS study record update · 2024-08-09A Randomized, Open-Label, Controlled, Phase III Study of SHR-A1921 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer
-
CLINICAL_TRIALS study record update · 2024-08-07A New Fast DWI-based Magnetic Resonance Protocol for Surveillance in Patients With a High Risk of Ovarian Cancer Recurrence During PARP-inhibitors Maintenance to Enhance Secondary Cytoreduction Results
-
CLINICAL_TRIALS study record update · 2024-08-07A Comparison of 2 Standard Doses of Bevacizumab in Combination With Chemotherapy in Epithelial Ovarian Cancer - a Pragmatic Trial
-
CLINICAL_TRIALS study record update · 2024-08-07Dose Escalation and Expansion Clinical Study to Evaluate the Safety and Efficacy of ELU001 in Subjects Who Have Advanced, Recurrent or Refractory FRα Overexpressing Tumors
-
CLINICAL_TRIALS study record update · 2024-08-06Phase 1b/2 Study of ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer
-
CLINICAL_TRIALS study record update · 2024-08-06A Phase 1/2 Open-label Study Investigating the Safety, Tolerability and Efficacy of ASP0739 as a Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors Known to Express NY-ESO-1
-
CLINICAL_TRIALS study record update · 2024-08-01A Phase 1 Evaluation of the Safety and Tolerability of Niraparib in Combination With Everolimus in Advanced Gynecologic Malignancies and Breast Cancer
-
CLINICAL_TRIALS study record update · 2024-08-01A Multicenter, Open Label, Single-arm Phase I/II Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Initial Efficacy of XS-02 Capsules in Patients With Advanced Solid Tumors